Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1L7DE
|
|||
| Drug Name |
GEM3PSCA
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
| Company |
Gemoab
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate stem cell antigen (PSCA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Gemoab. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.